Oral administration of synthetic selenium nanoparticles induced robust Th1 cytokine pattern after HBs antigen vaccination in mouse model

Journal of Infection and Public Health

Volumn 10, Issue 1, 2017, Pages 102-109

  Mahdavi, Mehdi ^a,b   Mavandadnejad, Faranak ^c   Yazdi, Mohammad H ^a,b   Faghfuri, Elnaz ^c   Hashemi, Hura ^c   Homayouni Oreh, Somayeh ^c   Farhoudi, Ramin ^b   Shahverdi, Ahmad R ^a,c  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b PASTEUR INSTITUTE OF IRAN   (Iran)

^c TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Hepatitis B vaccine; IFN ; Selenium nanoparticles; Th1 immune response

Indexed keywords

CYTOKINE; GAMMA INTERFERON; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN G2B; IMMUNOGLOBULIN M; INTERLEUKIN 4; PHOSPHATE BUFFERED SALINE; SELENIUM NANOPARTICLE; HEPATITIS B ANTIBODY; HEPATITIS B VACCINE; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; NANOPARTICLE; SELENIUM;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGLOBULIN BLOOD LEVEL; LYMPHOCYTE PROLIFERATION; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; TH1 CELL; TREATMENT OUTCOME; VACCINATION; VIRUS IMMUNITY; ANIMAL; BAGG ALBINO MOUSE; BLOOD; CELL PROLIFERATION; IMMUNOLOGY; ORAL DRUG ADMINISTRATION; SECRETION (PROCESS);

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CELL PROLIFERATION; CYTOKINES; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HEPATITIS B ANTIBODIES; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VACCINES; IMMUNOGLOBULIN G; IMMUNOGLOBULIN M; MICE, INBRED BALB C; NANOPARTICLES; SELENIUM; TH1 CELLS;

EID: 84962485062     PISSN: 18760341     EISSN: 1876035X     Source Type: Journal    
DOI: 10.1016/j.jiph.2016.02.006     Document Type: Article

References (16)

1. [1] Sunbul, M., Hepatitis B virus genotypes: global distribution and clinical importance. World J Gastroenterol 20:18 (2014), 5427–5434.
2. [2] Lavanchy, D., Hepatitis B virus epidemiology, disease burden, treatment, and current emerging prevention and control measures. J Viral Hepat 11 (2004), 97–107.
3. [3] Craven, D.E., Awdeh, Z.L., Kunches, L.M., Yunis, E.J., Dienstag, J.L., Werner, B.G., et al. Non-responsiveness to hepatitis B vaccine in health care workers. Results of revaccination and genetic typings. Ann Intern Med 105 (1986), 356–360.
4. [4] Dezfuli, H.T., Shahbazzadeh, D., Eidi, A., Bagheri, K.P., Pakravan, N., Amini, S., Aghasadeghi, M.R., Mahdavi, M., Induction of IFN-γ cytokine response against hepatitis B surface antigen using melittin. Gastroenterol Hepatol Bed Bench 7:2 (2014), 108–117.
5. [5] Guidotti, L.G., Chisari, F.V., Noncytolytic control of viral infections by the innate and adaptive immune response. Annu Rev Immunol 19 (2001), 65–91.
6. [6] Oleszycka, E., Lavelle, E.C., Immunomodulatory properties of the vaccine adjuvant alum. Curr Opin Immunol 28C (2014), 1–5.
7. [7] Tapiero, H., Townsend, D.M., Tew, K.D., The antioxidant role of selenium and seleno-compounds. Biomed Pharmacother 57 (2003), 134–144.
8. [8] Shakibaie, M., Shahverdi, A.R., Faramarzi, M.A., Hassanzadeh, G.R., Rahimi, H.R., Sabzevari, O., Acute and subacute toxicity of novel biogenic selenium nanoparticles in mice. Pharm Biol 51:1 (2013), 58–63.
9. [9] Yazdi, M.H., Mahdavi, M., Varastehmoradi, B., Faramarzi, M.A., Shahverdi, A.R., The immunostimulatory effect of biogenic selenium nanoparticles on the 4T1 breast cancer model: an in vivo study. Biol Trace Elem Res 149:1 (2012), 22–28.
10. [10] Xu, D.Z., Zhao, K., Guo, L.M., Li, L.J., Xie, Q., Ren, H., A randomized controlled phase IIb trial of antigen antibody immunogenic complex therapeutic vaccine in chronic hepatitis B patients. PLoS ONE, 3, 2008, 2565.
11. [11] Chen, D.S., Hepatitis B vaccination: the key towards elimination and eradication of hepatitis B. J Hepatol 50 (2009), 805–816.
12. [12] Cao, W., Qiu, Z., Zhu, T., Li, Y., Han, Y., Li, T., CD8+ T cell responses specific for hepatitis B virus core protein in patients with chronic hepatitis B virus infection. J Clin Virol 61:1 (2014), 40–46.
13. [13] Boni, C., Fisicaro, P., Valdatta, C., Amadei, B., Di Vincenzo, P., Giuberti, T., Characterization of hepatitis B virus (HBV)-specific T cell dysfunction in chronic HBV infection. J Virol 81 (2007), 4215–4225.
14. [14] Mizel, S.B., Bates, J.T., Flagellin as an adjuvant: cellular mechanisms and potential. J Immunol 185 (2010), 5677–5682.
15. [15] Thatte, J., Rath, S., Bal, V., Analysis of immunization route-related variation in the immune response to heat killed Salmonella typhimurium in mice. Infect Immun 63 (1995), 99–103.
16. [16] Alper, C.A., Krushall, M.S., Marcus-Bagley, D., Craven, D.E., Katz, A.J., Brink, S.J., Genetic prediction of nonresponse to hepatitis B vaccine. N Engl J Med 321 (1989), 708–712.